Be the first person to write a business review for BioSyntech, Inc.

Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.

BioTime, Inc. company was founded in 1990 and is headquartered in Alameda, California. BioTime, Inc. is a biomedical organization engaged in the development of synthetic plasma expanders and blood volume substitute solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine. The Company’s operating revenues have been generated primarily from licensing fees related to the sale of its plasma volume expander products, primarily Hextend. The company began to make its first stem cell research products available during the year ended December 31, 2008, but it had not yet generated significant revenues in that business segment.

BioTrove, researchers can mine the treasure trove of information encoded in genetic material... and still make it home in time for dinner. The company makes the OpenArray life science research systems that allow scientists to rapidly prepare and test multiple genetic samples at once. The system can perform more than 3,000 genetic tests simultaneously on a single slide and is used by laboratory researchers in gene expression and genotyping analysis. BioTrove was acquired by Life Technologies in late 2009. At the same time, the company's RapidFire sample preparation business was spun off into a new entity named BIOCIUS Life Sciences.

BioVest offers cell culture products, instruments, and related contract services to research institutions, biotech firms, and pharmaceutical companies. The company is also developing a therapeutic cancer vaccine for follicular non-Hodgkin's lymphoma that is customized for individual patient use. The candidate, dubbed BiovaxID, is undergoing late-stage clinical trials. Its AutovaxID product is a cell culture instrument designed to ease use of BiovaxID. BioVest is 76% owned by Accentia Biopharmaceuticals. Both BioVest and Accentia filed for Chapter 11 bankruptcy in 2008 and are restructuring their operations.

BioVex Group has developed a virus-containing vaccine which works to prevent and combat certain types of cancer and chronic infectious diseases. The company's lead product, OncoVEX, makes use of an altered virus to attack solid tumor cells but leave healthy cells intact. OncoVEX has shown promise in treating metastatic melanoma and the company has plans to vex other cancers such as pancreatic and colo-rectal cancers. After a brief stint as a publicly-traded company, in 2007 BioVex was taken private by a group of investors led by health science-oriented Triathlon Medical Ventures.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.